APA (7th ed.) Citation

Bissonnette, R., Maari, C., Forman, S., Bhatia, N., Lee, M., Fowler, J., . . . Guttman‐Yassky, E. (2019). The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermatitis: Results from a randomized double‐blind placebo‐controlled study. British Journal of Dermatology, 181(4), 733. https://doi.org/10.1111/bjd.17932

Chicago Style (17th ed.) Citation

Bissonnette, R., et al. "The Oral Janus Kinase/spleen Tyrosine Kinase Inhibitor ASN002 Demonstrates Efficacy and Improves Associated Systemic Inflammation in Patients with Moderate‐to‐severe Atopic Dermatitis: Results from a Randomized Double‐blind Placebo‐controlled Study." British Journal of Dermatology 181, no. 4 (2019): 733. https://doi.org/10.1111/bjd.17932.

MLA (9th ed.) Citation

Bissonnette, R., et al. "The Oral Janus Kinase/spleen Tyrosine Kinase Inhibitor ASN002 Demonstrates Efficacy and Improves Associated Systemic Inflammation in Patients with Moderate‐to‐severe Atopic Dermatitis: Results from a Randomized Double‐blind Placebo‐controlled Study." British Journal of Dermatology, vol. 181, no. 4, 2019, p. 733, https://doi.org/10.1111/bjd.17932.